文献速递肿瘤 PET/CT放射性药物与辐射防护

无症状癌症患者COVID-19肺炎的肺外肺受累18F-FDG PET-CT评估

Assessment of extra-parenchymal lung involvement in asymptomatic cancer patients with COVID-19 pneumonia detected on 18F-FDG PET-CT studies.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-09-08

该研究回顾了2020年2月至5月间1079例肿瘤18F-FDG PET-CT,纳入23例有肺部浸润疑似COVID-19且实验室数据可用的患者,其中14例确诊、9例对照,COVID-19肺炎患病率低(1.3%)。确诊患者中42.9%出现肺外肺表现,最常见为纵隔和肺门淋巴结FDG摄取(35.7%),其次为偶发肺栓塞(2例,14.3%)。结论认为无症状COVID-19肺炎癌症患者的PET-CT表现多局限于胸部结构,远处沉默性受累罕见,但肺栓塞是需特别关注的频繁且可能严重的发现。

要点

  • 无症状COVID-19肺炎癌症患者中42.9%出现肺外肺FDG摄取,以纵隔和肺门淋巴结最常见(35.7%)。
  • 偶发肺栓塞见于2例(14.3%)COVID-19患者,是需要特别关注的潜在严重发现。
  • 对照组仅1例(11.1%)出现肺外肺FDG摄取,位于纵隔、肺门和颈部淋巴结。

核心结论

  • 无症状COVID-19肺炎癌症患者的18F-FDG PET-CT表现更常局限于胸部结构,提示早期沉默性远处受累非常罕见。
  • 肺栓塞是频繁且可能严重的发现,需特别关注。

研究设计与样本

  • 回顾性研究,2020年2月2日至5月18日共行1079例肿瘤18F-FDG PET-CT。
  • 纳入23例有肺部浸润疑似COVID-19且实验室数据可用的患者,其中14例确诊COVID-19、9例对照,COVID-19肺炎患病率1.3%。

主要发现

  • COVID-19确诊患者中42.9%出现肺外肺表现,最常见为纵隔和肺门淋巴结FDG摄取(35.7%),其次为偶发肺栓塞(2例,14.3%)。
  • 对照组仅1例(11.1%)出现肺外肺FDG摄取,位于纵隔、肺门和颈部淋巴结。
  • COVID-19患者血清乳酸脱氢酶和D-二聚体趋于升高。
  • 两组鼻咽和肝脏SUVmax相似。

临床怎么用

  • 对无症状癌症患者行18F-FDG PET-CT时,若发现肺部浸润疑似COVID-19,应关注纵隔和肺门淋巴结FDG摄取及偶发肺栓塞。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lung involvement in patients with coronavirus disease 2019 (COVID-19) undergoing PET-CT has been previously reported. However, FDG uptake outside lung parenchyma was poorly characterized in detail. We evaluated the extra-parenchymal lung involvement in asymptomatic cancer patients with COVID-19 pneumonia through 18F-FDG PET-CT. METHODS: A total of 1079 oncologic 18F-FDG PET-CT were performed between February 2 and May 18, 2020. Confirmed COVID-19 pneumonia was defined as characteristic ground-glass bilateral CT infiltrates and positive genetic/serologic tests. Nonmetastatic extra-parenchymal lung PET-CT findings were evaluated through qualitative (visual), quantitative (measurements on CT), and semiquantitative (maximum standardized uptake value: SUVmax on PET) interpretation. Clinical data, blood tests, and PET-CT results were compared between patients with and without COVID-19 pneumonia. RESULTS: A total of 23 18F-FDG PET-CT scans with pulmonary infiltrates suggestive of COVID-19 and available laboratory data were included: 14 positive (cases) and 9 negative (controls) for COVID-19 infection, representing a low prevalence of COVID-19 pneumonia (1.3%). Serum lactate dehydrogenase and D-dimers tended to be increased in COVID-19 cases. Extra-parenchymal lung findings were found in 42.9% of patients with COVID-19, most frequently as mediastinal and hilar nodes with 18F-FDG uptake (35.7%), followed by incidental pulmonary embolism in two patients (14.3%). In the control group, extra-pulmonary findings were observed in a single patient (11.1%) with 18F-FDG uptake located to mediastinal, hilar, and cervical nodes. Nasopharyngeal and hepatic SUVmax were similar in both groups. CONCLUSION: In cancer patients with asymptomatic COVID-19 pneumonia, 18F-FDG PET-CT findings are more frequently limited to thoracic structures, suggesting that an early and silent distant involvement is very rare. Pulmonary embolism is a frequent and potentially severe finding raising special concern. PET-CT can provide new pathogenic insights about this novel disease.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wakfie-Corieh CG, Blanes García AM, Ferrando-Castagnetto F, et al. Assessment of extra-parenchymal lung involvement in asymptomatic cancer patients with COVID-19 pneumonia detected on 18F-FDG PET-CT studies. Eur J Nucl Med Mol Imaging. 2020. PMID: 32901353. doi:10.1007/s00259-020-05019-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。